- Call Us: +91-9988543543
26th June 2025 | By Admin
The page outlines several reasons (or selling-points) to choose BHS as a supplier / manufacturer:
WHO-GMP certified manufacturing: BHS claims compliance with WHO-GMP standards, meaning their manufacturing units follow stringent quality guidelines.
Reasonable / competitive pricing: They say their pricing structure is favourable, allowing “small and medium-sized” distributors to profit without compromising on quality.
Regular product availability: They promise consistent stock, timely delivery and ongoing supply — which they position as a competitive advantage especially where demand for UTI drugs is high.
Attractive PCD-franchise benefits: According to them, this includes “monopoly rights” (exclusive territorial rights), marketing support/promotional materials, custom packaging/branding under the partner’s brand name, low investment thresholds, etc.
Third-party manufacturing support: For businesses wanting to expand their product line, BHS offers turnkey third-party manufacturing services — from formulation to packaging and documentation.
The page gives reasons why the combination of flavoxate and nitrofurantoin is a “good option” for PCD pharma-franchise business:
Increasing demand for UTI (urinary tract infection) medicines — they note that UTIs are becoming more common, making UTI drugs consistently in demand.
The “dual action formula” — implying flavoxate (for urinary tract spasms) + nitrofurantoin (an antibiotic) offers better / broader therapy, which according to them enhances patient compliance and thus market viability
They claim the product still has “fewer market competitors” (i.e. many pharma companies reportedly haven’t explored this specific combination), giving potential for good market share for early entrants.
They suggest the product is viable across both rural and urban markets — implying a wide target market and good opportunity for “market penetration.”
According to the page, BHS offers:
Monopoly-based franchise rights (to avoid competition from other distributors of the same brand/product in your region)
Promotional support: marketing aids (MR bags, product cards, visual aids), which helps in promotions if you become a franchise partner.
Custom packaging / branding: they offer to manufacture the tablets and package them under your brand name (private label) if desired.
Dedicated support team: to assist with product training, order tracking, regulatory documentation and logistics/delivery — aiming for a “seamless business experience.”
The claims about “WHO-GMP certification,” “DCGI approval,” and “monopoly rights” are stated by the company — but I did not find independent, verifiable documentation on a regulatory database (at least not from the sources reviewed) confirming that the flavoxate + nitrofurantoin tablet combination from BHS is indeed DCGI-approved.
There’s no listing of specific product names or strengths (dosage) on the page — the page is more of a marketing pitch for franchise partners rather than a detailed product catalog.
Information about safety, regulatory compliance, actual availability, quality audits, or third-party reviews / feedback is missing. The page presents only the company’s own claims.
If you want — I can try to check publicly available drug-regulatory databases in India (or recent pharma-company registries) to verify if BHS’s flavoxate + nitrofurantoin combination is officially registered / approved, as of now.
Do you want me to proceed with that check for you?
